Search Results

You are looking at 31 - 40 of 73 items for :

  • "zoledronic acid" x
Clear All
Full access

Noa Efrat Ben-Baruch, Ron Bose, Shyam M. Kavuri, Cynthia X. Ma and Matthew J. Ellis

treated with oophorectomy, letrozole, and zoledronic acid, and experienced an excellent clinical and radiologic response. In 2005, a new breast mass was found in the same breast and biopsy results revealed invasive ductal carcinoma that was hormone

Full access

health in patients, including surgical options and bisphosphonates. She provided an overview of clinical trial data showing the equivalence of pamidronate versus zoledronic acid, discussed data showing the survival advantage with zoledronic acid compared

Full access

Shaji K. Kumar, Natalie S. Callander, Melissa Alsina, Djordje Atanackovic, J. Sybil Biermann, Jason C. Chandler, Caitlin Costello, Matthew Faiman, Henry C. Fung, Cristina Gasparetto, Kelly Godby, Craig Hofmeister, Leona Holmberg, Sarah Holstein, Carol Ann Huff, Adetola Kassim, Michaela Liedtke, Thomas Martin, James Omel, Noopur Raje, Frederic J. Reu, Seema Singhal, George Somlo, Keith Stockerl-Goldstein, Steven P. Treon, Donna Weber, Joachim Yahalom, Dorothy A. Shead and Rashmi Kumar

, 164 Zoledronic acid has equivalent benefits. 165 Results from the study conducted by Zervas et al 166 show a 9.5-fold greater risk for the development of osteonecrosis of the jaw with zoledronic acid compared with pamidronate. Patients who are on

Full access

Ruben Niesvizky and Ashraf Z. Badros

– 41 The updated zoledronic acid prescribing information 42 and the updated ASCO guidelines 37 recommend a reduced dosage for patients with an estimated creatinine clearance between 30 and 60 mL/min. The dose should be administered over a period of

Full access

James L. Mohler, Philip W. Kantoff, Andrew J. Armstrong, Robert R. Bahnson, Michael Cohen, Anthony Victor D’Amico, James A. Eastham, Charles A. Enke, Thomas A. Farrington, Celestia S. Higano, Eric Mark Horwitz, Mark H. Kawachi, Michael Kuettel, Richard J. Lee, Gary R. MacVicar, Arnold W. Malcolm, David Miller, Elizabeth R. Plimack, Julio M. Pow-Sang, Sylvia Richey, Mack Roach III, Eric Rohren, Stan Rosenfeld, Eric J. Small, Sandy Srinivas, Cy Stein, Seth A. Strope, Jonathan Tward, Patrick C. Walsh, Dorothy A. Shead and Maria Ho

.8 months). This result rendered radium-223 the first bone-targeting agent to provide a survival advantage; benefits from other agents, such as zoledronic acid and denosumab, are limited to delay of SREs in the setting of bone metastases. 24 , 25 The effect

Full access

Miren Gaztañaga and Juanita Crook

zoledronic acid (4 mg intravenously annually) or alendronate (70 mg orally weekly) is recommended when the absolute fracture risk is significant. 6 Denosumab, a human monoclonal antibody against RANK (receptor activator of nuclear factor κB) ligand, has been

Full access

Kenneth C. Anderson, Melissa Alsina, William Bensinger, J. Sybil Biermann, Asher Chanan-Khan, Adam D. Cohen, Steven Devine, Benjamin Djulbegovic, Edward A. Faber Jr., Cristina Gasparetto, Carol Ann Huff, Adetola Kassim, Bruno C. Medeiros, Ruby Meredith, Noopur Raje, Jeffrey Schriber, Seema Singhal, George Somlo, Keith Stockerl-Goldstein, Steven P. Treon, Guido Tricot, Donna M. Weber, Joachim Yahalom and Furhan Yunus

and at least one lytic lesion. 188 , 189 Zoledronic acid is more potent, can be administered more rapidly, and has equivalent benefits. 190 Results from the study conducted by Zervas et al. 191 show a 9.5-fold greater risk for the development of

Full access

James L. Mohler, Emmanuel S. Antonarakis, Andrew J. Armstrong, Anthony V. D’Amico, Brian J. Davis, Tanya Dorff, James A. Eastham, Charles A. Enke, Thomas A. Farrington, Celestia S. Higano, Eric Mark Horwitz, Michael Hurwitz, Joseph E. Ippolito, Christopher J. Kane, Michael R. Kuettel, Joshua M. Lang, Jesse McKenney, George Netto, David F. Penson, Elizabeth R. Plimack, Julio M. Pow-Sang, Thomas J. Pugh, Sylvia Richey, Mack Roach III, Stan Rosenfeld, Edward Schaeffer, Ahmad Shabsigh, Eric J. Small, Daniel E. Spratt, Sandy Srinivas, Jonathan Tward, Dorothy A. Shead and Deborah A. Freedman-Cass

mutations. Agents Related to Bone Health in CRPC In a multicenter study, 643 men with CRPC and asymptomatic or minimally symptomatic bone metastases were randomized to intravenous zoledronic acid every 3 weeks or placebo. 228 At 15 months, fewer men in the

Full access

Shaji K. Kumar, Natalie S. Callander, Kehinde Adekola, Larry Anderson, Muhamed Baljevic, Erica Campagnaro, Jorge J. Castillo, Jason C. Chandler, Caitlin Costello, Yvonne Efebera, Matthew Faiman, Alfred Garfall, Kelly Godby, Jens Hillengass, Leona Holmberg, Myo Htut, Carol Ann Huff, Yubin Kang, Malin Hultcrantz, Sarah Larson, Michaela Liedtke, Thomas Martin, James Omel, Kenneth Shain, Douglas Sborov, Keith Stockerl-Goldstein, Donna Weber, Jennifer Keller and Rashmi Kumar

pain and bone-related complications, improve performance status, and, importantly, preserve quality of life in patients with Durie-Salmon stage III MM and at least one lytic lesion. 171 , 172 Zoledronic acid has equivalent benefits. 173 Results from

Full access

Philip J. Saylor and Matthew R. Smith

similar claims-based analysis also found a significant association between GnRH agonist treatment and clinical fractures (relative risk [RR], 1.21; P < .001). 65 Bisphosphonates, including pamidronate, 66 , 67 zoledronic acid, 68 , 69